Success Metrics

Clinical Success Rate
84.2%

Based on 48 completed trials

Completion Rate
84%(48/57)
Active Trials
81(49%)
Results Posted
135%(65 trials)
Terminated
9(5%)

Phase Distribution

Ph early_phase_1
6
4%
Ph not_applicable
17
10%
Ph phase_1
20
12%
Ph phase_2
81
49%
Ph phase_3
31
19%
Ph phase_4
10
6%

Phase Distribution

26

Early Stage

81

Mid Stage

41

Late Stage

Phase Distribution165 total trials
Early Phase 1First-in-human
6(3.6%)
Phase 1Safety & dosage
20(12.1%)
Phase 2Efficacy & side effects
81(49.1%)
Phase 3Large-scale testing
31(18.8%)
Phase 4Post-market surveillance
10(6.1%)
N/ANon-phased studies
17(10.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.6%

48 of 67 finished

Non-Completion Rate

28.4%

19 ended early

Currently Active

81

trials recruiting

Total Trials

165

all time

Status Distribution
Active(90)
Completed(48)
Terminated(19)
Other(8)

Detailed Status

Completed48
Active, not recruiting45
Recruiting36
Withdrawn10
Terminated9
Not yet recruiting9

Development Timeline

Analytics

Development Status

Total Trials
165
Active
81
Success Rate
84.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (3.6%)
Phase 120 (12.1%)
Phase 281 (49.1%)
Phase 331 (18.8%)
Phase 410 (6.1%)
N/A17 (10.3%)

Trials by Status

completed4829%
active_not_recruiting4527%
terminated95%
not_yet_recruiting95%
recruiting3622%
withdrawn106%
unknown74%
suspended11%

Recent Activity

Clinical Trials (165)

Showing 20 of 165 trialsScroll for more
NCT06639074Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Recruiting
NCT05751668Phase 2

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

Active Not Recruiting
NCT07215910Phase 3

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Recruiting
NCT02115282Phase 3

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Active Not Recruiting
NCT03371719Phase 2

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

Active Not Recruiting
NCT01575548Phase 3

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Active Not Recruiting
NCT05432804Phase 1

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recruiting
NCT04858334Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Recruiting
NCT00433511Phase 3

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Active Not Recruiting
NCT02194738Not Applicable

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Active Not Recruiting
NCT01638546Phase 2

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Active Not Recruiting
NCT03996265Phase 3

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Active Not Recruiting
NCT05237960Phase 2

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Active Not Recruiting
NCT03418038Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recruiting
NCT06855524Phase 2

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer

Recruiting
NCT06334016Early Phase 1

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

Not Yet Recruiting
NCT05564390Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting
NCT06009926Phase 2

Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters

Active Not Recruiting
NCT03375320Phase 3

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Active Not Recruiting
NCT03471364Early Phase 1

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

Completed

Drug Details

Intervention Type
DRUG
Total Trials
165